PREFRIN-A
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREFRIN-A (PREFRIN-A).
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
| Metabolism | Phenylephrine undergoes extensive first-pass metabolism by monoamine oxidase (MAO) in the liver and gut; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to a hepatotoxic metabolite NAPQI. |
| Excretion | Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites. |
| Half-life | Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism. |
| Protein binding | Phenylephrine: 50-60% bound to albumin and alpha-1-acid glycoprotein; Antazoline: ~20% bound to albumin. |
| Volume of Distribution | Phenylephrine: Vd ~0.5 L/kg (distributes primarily into extracellular fluid); Antazoline: Vd ~2 L/kg (extensive tissue distribution). |
| Bioavailability | Ocular: <1% systemic bioavailability after topical administration; intranasal: 10-20% systemic bioavailability; oral: 2-5% due to first-pass metabolism. |
| Onset of Action | Ocular: 10-30 minutes after topical administration; intranasal: 5-15 minutes. |
| Duration of Action | Ocular: 4-8 hours (decongestant effect); intranasal: 4-6 hours (vasoconstriction). |
| Molecular Weight | Phenylephrine: 167.21 Da; Antazoline: 265.35 Da (combination drug average approximately 216 Da) |
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children ≥6 years: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily. Children <6 years: not recommended. |
| Geriatric use | Use with caution due to increased risk of systemic absorption and adverse effects; consider lowest effective dose and frequency. |
| 1st trimester | Avoid due to potential teratogenic effects from the decongestant component (phenylephrine). Animal studies have shown adverse effects, and limited human data suggest possible association with gastroschisis. |
| 2nd trimester | Use with caution only if clearly needed. Phenylephrine may cause maternal hypertension and reduced placental perfusion. Antazoline (antihistamine) has limited safety data but is generally considered low risk. |
| 3rd trimester | Avoid near term. Phenylephrine may cause uterine contractions and reduce placental blood flow, potentially leading to fetal hypoxia. Antazoline has no specific risks reported. |
Clinical note
Comprehensive clinical and safety monograph for PREFRIN-A (PREFRIN-A).
| Placental transfer | The phenylephrine component is known to cross the placenta, with potential for fetal exposure. Antazoline likely crosses as well, though data are limited. Both are low molecular weight compounds that can readily cross the placental barrier. |
| Breastfeeding |
■ FDA Black Box Warning
None.
| Serious Effects |
Narrow-angle glaucomaSevere hypertension or coronary artery diseaseConcurrent use of MAO inhibitors or within 14 daysHypersensitivity to any component
| Precautions | Avoid use in patients with hypertension, hyperthyroidism, diabetes, or cardiovascular disease. Risk of hepatotoxicity with acetaminophen overdose. Do not exceed recommended dose. Avoid concurrent use with MAO inhibitors. |
| Food/Dietary | Avoid alcohol and products containing caffeine or other stimulants as they may increase the risk of cardiovascular adverse effects. No specific food restrictions beyond maintaining hydration. |
| Clinical Pearls |
Loading safety data…
| Phenylephrine is excreted into breast milk in small amounts but is unlikely to affect the nursing infant at recommended doses. However, it may reduce milk production due to vasoconstriction. Antazoline is also excreted in small amounts. Use with caution and monitor the infant for signs of irritability or drowsiness. |
| Lactation Rating | L3: Moderately Safe |
| Teratogenic Risk | Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction and reduced placental perfusion; risk of fetal hypoxia in third trimester. Pyrilamine: Class B in pregnancy; animal studies show no fetal harm. Avoid in first trimester due to theoretical risk of vasoconstriction. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate; phenylephrine may cause hypertension or reflex bradycardia. In third trimester, monitor for uterine activity and fetal heart rate if used long-term or at high doses. |
| Fertility Effects | No known effects on fertility in humans. Animal studies with pyrilamine show no impairment. Phenylephrine may theoretically affect uterine perfusion but no fertility data. |
| Prefrin-A combines phenylephrine (alpha-1 agonist vasoconstrictor) with pyrilamine (first-generation antihistamine). Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, or narrow-angle glaucoma. Avoid in patients taking MAO inhibitors or within 14 days of discontinuation. Rebound congestion can occur with prolonged use (>3 days). Monitor for CNS depression or paradoxical excitation in children. |
| Patient Advice | Use exactly as directed; do not use for more than 3 days to avoid rebound congestion. · Avoid driving or operating machinery if drowsiness occurs, especially when combined with alcohol or other CNS depressants. · Do not use if you have high blood pressure, heart disease, thyroid problems, diabetes, or glaucoma unless directed by a doctor. · Discontinue use and consult a doctor if symptoms persist or worsen, or if you experience severe dizziness, headache, or irregular heartbeat. · Store at room temperature away from moisture and heat. Keep out of reach of children. |